We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Quest Diagnostics Inc. (DGX - Free Report) and Clinical Genomics, a major player in the field of colorectal cancer detection, jointly announced the FDA clearance of the latter’s InSure ONE.
With the FDA approval, Quest Diagnostics will make InSure ONE available to its broad base of physicians, organized provider groups and Accountable Care Organizations (ACOs) across the United States. InSure ONE is expected to be commercially available in early 2018. This development will remain a part of Quest Diagnostics’ consistent effort to successfully pave its way through the growing field of cancer diagnostics.
As a useful at-home collection fecal immunochemical test (FIT), InSure ONE improves compliance for screening programs. Among other InSure FIT tests, InSure ONE detects human hemoglobin from blood in fecal samples to aid in the detection of lower gastrointestinal bleeding. While other FIT tests require two samples, InSure ONE needs just a single specimen to run the screening successfully.
Given the fact that FIT has been accepted as the guideline recommended for screening programs for an early detection of adenomatous polyps, precursors to cancer and colorectal cancer (in individuals of average risk starting at age 50 years), the role of InSure FIT tests is gaining more importance by the day. Considering this situation, both the companies view that this uncomplicated procedure of InSure ONE may better fix the problem of patient non-participation for screening programs as well.
The latest strategic development with Clinical Genomics is in sync with Quest Diagnostics’ goal to gain a leadership position in the high-potential global oncology diagnostic market. Notably, Quest Diagnostics has recently acquired Med Fusion and Clear Point forming a national precision oncology center of expertise.
Per the data provided by American Cancer Society, nearly 1.7 million people are expected to be diagnosed with cancer in the United States by the end of 2017. Also, per Markets and Markets, the global cancer diagnostics market is expected to reach a level worth $13.1 billion by 2020 at a CAGR of 12.9% during 2015-2020. Accordingly, we are upbeat about a promising customer adoption rate of InSure ONE down the line.
Quest Diagnostics outperformed the broader industry with respect to share price movement over the past six months. As per the last share price movement, the company has lost 14.5% in this period, narrower than the 17.2% loss of the broader industry.
PetMed has a long-term expected earnings growth rate of 10%. The stock has soared roughly 78.6% over a year.
Luminex has a long-term expected earnings growth rate of 16.3%. The stock has gained 1.9% in a year.
Myriad Genetics has a long-term expected earnings growth rate of 15%. The stock has surged 76.4% in a year’s time.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Quest Diagnostics, Clinical Genomics Ally, Oncology Strong
Quest Diagnostics Inc. (DGX - Free Report) and Clinical Genomics, a major player in the field of colorectal cancer detection, jointly announced the FDA clearance of the latter’s InSure ONE.
With the FDA approval, Quest Diagnostics will make InSure ONE available to its broad base of physicians, organized provider groups and Accountable Care Organizations (ACOs) across the United States. InSure ONE is expected to be commercially available in early 2018. This development will remain a part of Quest Diagnostics’ consistent effort to successfully pave its way through the growing field of cancer diagnostics.
As a useful at-home collection fecal immunochemical test (FIT), InSure ONE improves compliance for screening programs. Among other InSure FIT tests, InSure ONE detects human hemoglobin from blood in fecal samples to aid in the detection of lower gastrointestinal bleeding. While other FIT tests require two samples, InSure ONE needs just a single specimen to run the screening successfully.
Given the fact that FIT has been accepted as the guideline recommended for screening programs for an early detection of adenomatous polyps, precursors to cancer and colorectal cancer (in individuals of average risk starting at age 50 years), the role of InSure FIT tests is gaining more importance by the day. Considering this situation, both the companies view that this uncomplicated procedure of InSure ONE may better fix the problem of patient non-participation for screening programs as well.
The latest strategic development with Clinical Genomics is in sync with Quest Diagnostics’ goal to gain a leadership position in the high-potential global oncology diagnostic market. Notably, Quest Diagnostics has recently acquired Med Fusion and Clear Point forming a national precision oncology center of expertise.
Per the data provided by American Cancer Society, nearly 1.7 million people are expected to be diagnosed with cancer in the United States by the end of 2017. Also, per Markets and Markets, the global cancer diagnostics market is expected to reach a level worth $13.1 billion by 2020 at a CAGR of 12.9% during 2015-2020. Accordingly, we are upbeat about a promising customer adoption rate of InSure ONE down the line.
Quest Diagnostics outperformed the broader industry with respect to share price movement over the past six months. As per the last share price movement, the company has lost 14.5% in this period, narrower than the 17.2% loss of the broader industry.
Zacks Rank & Key Picks
Quest Diagnostics carries a Zacks Rank #3 (Hold). A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. (PETS - Free Report) , Luminex Corp. and Myriad Genetics, Inc. (MYGN - Free Report) , all three sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
PetMed has a long-term expected earnings growth rate of 10%. The stock has soared roughly 78.6% over a year.
Luminex has a long-term expected earnings growth rate of 16.3%. The stock has gained 1.9% in a year.
Myriad Genetics has a long-term expected earnings growth rate of 15%. The stock has surged 76.4% in a year’s time.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>